1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (011) 39 06 22541456
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Treatment of 72 newly diagnosed Waldenström macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone
Results and cost analysis
Article first published online: 20 DEC 2004
DOI: 10.1002/cncr.20826
Copyright © 2004 American Cancer Society
Additional Information
How to Cite
Annibali, O., Petrucci, M. T., Martini, V., Tirindelli, M. C., Levi, A., Fossati, C., Bianco, P. D., Mandelli, F., Foa, R. and Avvisati, G. (2005), Treatment of 72 newly diagnosed Waldenström macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone. Cancer, 103: 582–587. doi: 10.1002/cncr.20826
Publication History
- Issue published online: 20 JAN 2005
- Article first published online: 20 DEC 2004
- Manuscript Accepted: 18 OCT 2004
- Manuscript Revised: 6 OCT 2004
- Manuscript Received: 6 JUL 2004
REFERENCES
- 1. Incipient myelomatotosis or “essential” hyperglobulinemia with fibrinogenopenia—a new syndrome? Acta Med Scand. 1944; 117: 216–247.Direct Link:
- 2. Macroglobulinemia: a review. Haematologica. 1986; 71: 437–441.
- 3, . Waldenström's macroglobulinemia. Blood. 1994; 83: 1452–1459.
- 4, , , , . Waldenström's macroglobulinemia: clinical features, complications and management. J Clin Oncol. 2000; 18: 214–226.
- 5, , . Waldenström's macroglobulinaemia. Lancet Oncol. 2003; 4: 679–685.
- 6. Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-94. Cancer. 1998; 82: 1078–1081.
- 7. Treatment for Waldenström's macroglobulinemia. Ann Oncol. 2004; 15: 550–558.
- 8, , , et al. Multicenter Phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmocytoid lymphoma, Waldenström's macroglobulinemia and mantle cell lymphoma. J Clin Oncol. 1999; 17: 546–553.
- 9, , , et al. Prognostic factors and response to fludarabine therapy in patients with Waldenström's macroglobulinemia: results of a United States intergroup trial (Southwest Oncology Group S9003). Blood. 2001; 98: 41–48.
- 10, , , et al. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol. 1994; 12: 2694–2698.
- 11, , , , , . First-line treatment of Waldenström's disease with cladribine. Ann Hematol. 1997; 74: 7–10.
- 12, , , . Bolus administration of cladribine in the treatment of Waldenström's macroglobulinaemia. Br J Haematol. 1998; 103: 690–695.Direct Link:
- 13, , , , . Cladribine for Waldenström's macroglobulinaemia. Br J Haematol. 1999; 104: 933–934.Direct Link:
- 14, , , , , . Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia. Eur J Haematol. 1999; 63: 35–41.Direct Link:
- 15, , , , , . 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenström's macroglobulinemia. Semin Oncol. 2003; 30: 243–247.
- 16, , , et al. Waldenström macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol. 2000; 108: 737–742.Direct Link:
- 17, , , et al. Treatment recommendations in Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol. 2003; 30: 121–126.
- 18, , , , . Waldenström's macroglobulinemia: results of combined oral treatment in 34 newly diagnosed patients. J Intern Med. 1989; 226: 443–447.
- 19, , , . Waldenström's macroglobulinemia: long term results with the M-2 protocol. Cancer Invest. 1991; 9: 1–7.
- 20, , , , . Fludarabine therapy in macroglobulinemic lymphoma. Blood. 1990; 75: 1928–1931.
- 21, , , et al. Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol. 2002; 20: 2327–2333.
- 22, , , et al. Treatment of Waldenström's macroglobulinemia with thalidomide. J Clin Oncol. 2002; 19: 3596–3601.